Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Social determinants of health shape treatment course and long term outcomes in patients with high-risk myeloproliferative neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

NANatasha Amjed

Discussion

Loading...

Member takes

Overview

Cohort analysis reveals social determinants influence treatment course and health outcomes in myeloproliferative neoplasms, suggesting barriers to care exist.

Key Points

  • To investigate how social determinants affect treatment and disease outcomes in patients with high-risk myeloproliferative neoplasms.
  • Retrospective cohort analysis of patients diagnosed with high-risk Polycythemia Vera or Essential Thrombocythemia
  • Data collected from a multi-institutional database and analyzed for social risk factors
  • Frailty index calculated using 18 conditions and compared across demographic groups
  • Delays in diagnosis observed in patients from medically underserved areas, averaging 2.6 years later
  • Higher poverty rates linked to increased risk of myocardial infarction and stroke
  • Significant disparities in healthcare utilization noted, with African Americans having more visits and hospitalizations than Whites

Cite This Study

Natasha Amjed (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbe2https://doi.org/10.1182/blood-2025-6406
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Predictors of fibrotic progression in myeloproliferative neoplasms: A real-world retrospective cohort study.2026
  2. 2Thrombotic Events and Overall Survival in BCR-ABL1 Negative Myeloproliferative Neoplasms: A Single-Center Analysis2026
  3. 3Epidemiology and outcomes of patients with myeloproliferative neoplasms in the United States: A SEER database analysis, years 2000-20212025
  4. 4Clinical features, management, and outcomes of adolescents and young adults with myeloproliferative neoplasms.2026
  5. 5Predictors of Symptom Scores in Myeloproliferative Neoplasms: A Real‐World Retrospective Cohort Study2025